The price of zanubrutinib varies due to factors such as drug specifications, regions, and medical insurance policies. It generally ranges from USD 865 to 1,500 per box (equivalent to approximately a one-month dosage), and the actual selling price shall prevail at hospitals or formal pharmacies.
As a prescription drug, it must be used strictly under the guidance of a physician. Patients are prohibited from purchasing the drug or adjusting the dosage regimen without medical authorization.
Key Factors Affecting the Price
Drug Specifications
Prices differ across various dosage forms (e.g., capsules, tablets) or strengths (e.g., 80mg, 160mg). The selection should be based on the patient’s individualized treatment plan.
Regional Policy Disparities
Regional variations in medical insurance reimbursement rates, hospital procurement costs, and pharmacy pricing strategies may cause price fluctuations. Zanubrutinib has been incorporated into the local medical insurance catalogs in some cities, reducing patients’ out-of-pocket ratio to 30%–50%.
Purchase Channels
Prices at hospital pharmacies and licensed retail pharmacies are basically consistent. However, patients must be vigilant against the risk of counterfeit medications from unregulated channels.
Recommendations for Medication and Financial Burden Alleviation
Medical Insurance & Patient Assistance Programs
Zanubrutinib has been included in the National Reimbursement Drug List (2023), with indications restricted to patients with specific types of lymphoma. It is recommended to consult the attending physician to confirm reimbursement eligibility. Certain pharmaceutical companies or public welfare organizations provide patient assistance programs to further reduce treatment costs.
Medical Care & Medication Guidance
Dosage adjustment of zanubrutinib should be based on disease progression and adverse reaction monitoring. Patients are required to undergo regular re-examinations, including complete blood count, liver and renal function tests, and maintain close communication with the attending physician.
In case of significant financial pressure, patients are advised to inquire about fee reduction and exemption policies through formal channels at medical institutions or pharmaceutical companies, to avoid compromising therapeutic efficacy due to unauthorized drug discontinuation or substitution.
